Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

Exclusion Criteria

• •Neovascularization secondary to any other condition than AMD in the study eye
• •Blood occupying greater than 50% of the AMD lesion, or blood \> 1.0 sq. mm underlying the fovea
• •PED without associated subretinal fluid and/or cystic retinal changes
• •Clinical evidence of diabetic retinopathy or diabetic macular edema in the study eye
• •Confounding ocular conditions in the study eye which will affect interpretation of OCT, VA or assessment of macular appearance (e.g., cataract, epiretinal membrane, retinal vascular occlusive disease)
• •Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study eye or any condition preventing VA improvement
• •Uncontrolled glaucoma in the study eye, or currently receiving topical glaucoma medication in the study eye